Pfizer (PFE.N), opens new tab will sell its remaining stake in British consumer healthcare group Haleon (HLN.L), opens new tab, the companies said on Tuesday.
Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon, created in a merger of GSK (GSK.L), opens new tab and Pfizer's consumer healthcare businesses in 2019, and spun off in 2022.
Under the deal, the Sensodyne maker has agreed to buy back shares worth $220 million from Pfizer, currently its largest shareholder.
GSK, which initially owned nearly 13% of the firm, sold its entire stake in May 2024.
Following Pfizer's disposal, BlackRock Investment Management (UK) Ltd, a unit of BlackRock (BLK.N), opens new tab, will become Haleon's largest shareholder with over a 5% stake, according to data compiled by LSEG.
Haleon in February said its 2025 revenue and profit growth weighted to the second half of the year.
